Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 4/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3296644 | 0.84 | ALOX5 (0.40) | GABRA1GABRB2MAPTL3MBTL1TAAR1 | |
| SCHEMBL3296614 | 0.82 | MAPT (0.51) | GABRA1GABRB2MAPTNPSR1L3MBTL1 | |
| SCHEMBL3296107 | 0.78 | L3MBTL1 (0.45) | MAPTNPSR1L3MBTL1TP53 | |
| SCHEMBL3300208 | 0.77 | — | — | |
| SCHEMBL3302642 | 0.74 | GABRA1 (0.39) | GABRA1GABRB2MAPTNPSR1L3MBTL1 | |
| SCHEMBL3295521 | 0.74 | PTGS2 (0.35) | — | |
| SCHEMBL3298439 | 0.74 | GABRA1 (0.40) | GABRA1GABRB2MAPTNPSR1L3MBTL1 | |
| SCHEMBL3294191 | 0.71 | GABRA1 (0.38) | GABRA1GABRB2MAPTL3MBTL1KCNH2 | |
| SCHEMBL3303338 | 0.70 | MAPT (0.40) | GABRA1GABRB2MAPTNPSR1L3MBTL1 | |
| SCHEMBL3301620 | 0.68 | GRK6 (0.47) | MAPTNPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741393-B2 | Organic silicon-based compound and method of producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-22 | — | — | US | disclosed |
| US-20070203275-A1 | Organic Silicon-Based Compound And Method Of Producing The Same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203275-A1 | Organic Silicon-Based Compound And Method Of Producing The Same | ARSA, OR10J3, HDAC10 | GABRA1 4115/4885GABRB2 4381/4885MAPT 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.